Conflict of interest claim over UK OTC move

29 March 2009

The UK government is considering a proposal to allow up to 5,000 general practitioners to sell over-the-counter drugs in remote parts of the  country where pharmacy services are limited. Norman Lamb, a spokesman  for the opposition Liberal Democrat party, denounced the idea as  "potentially dangerous," adding that it could "risk undermining the  fundamental relationship between GP and patient."

Under current rules, some doctors are allowed to dispense prescription  drugs, collecting the appropriate fees from the National Health Service.  The change being examined would mean that OTC products could be bought  without a consultation, with the profits "benefit[ing] local health  services."

However, the General Medical Council, which would investigate complaints  against individual doctors, told the Marketletter that allegations of  conflict of interest over the sale of drugs are extremely rare, and that  physicians are bound to maintain an "open and honest" relationship  with the patient about fincial interests.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight